quaratusugene ozeplasmid
Gene therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2021 (NCT04486833)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor suppressor candidate 2Supplementation
supplementation - FUS1
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594390 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05703971 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2023 | Genprex, Inc. |
| NCT05062980 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2021 | Genprex, Inc., Washington University in St. Louis |
| NCT04486833 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2021 | Genprex, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genprex, Inc. | For profit | 3 | 3 | 1 | 2021 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1